1. Supriya Lifescience
stock logo

100% Buy

Supriya Lifescience Share Price

SUPRIYA

₹398.35+₹14.35 (3.74%) TodayLast updated on 14 Jun, 2024 | 03:59 PM IST
₹382.00₹402.95
L
Show Current Price
H
  • News

  • Company overview

  • Fundamentals

  • Events

  • More

Company overview

Financial performance

arrow

Market cap

Market Cap Switch₹3,091 Crs

Open

₹389.75

Close

₹384.00

Circuit range

₹460.80 - ₹307.20

Day range

₹382.00 - ₹402.95

Year range

₹233.30 - ₹424.00

Volume

10,87,337

Avg. traded

₹397.18

Revenue (12m)

₹570 Crs

Supriya Lifescience

Supriya Lifescience Limited is an Indian pharmaceutical company. It was established in 1987 and is headquartered in Mumbai. It is a prominent global producer of active pharmaceutical ingredients (APIs).

In API manufacturing, the company specialises in products across diverse therapeutic segments such as anti-histamines, anti-allergics, vitamins, anaesthetics and anti-asthmatics.

The company has a worldwide presence, reaching 86 countries. It’s domestic operations are spread across 12 states in India. Its product portfolio of active pharmaceutical ingredients includes more than 38 products.

The market capitalisation of Supriya Lifescience Limited stood at over ₹2,400 crore as of January 19, 2024. Supriya Lifescience share price has gained 42% in the last three years.

Supriya Lifescience Limited business operations

Supriya Lifescience Limited is a major supplier of active pharmaceutical ingredients (APIs) globally. It ensures efficient procurement from both Indian and global sources including China, South Korea and Belgium.

The company serves many well-known global pharmaceutical firms. A few of them are Syntec Do Brasil LTDA, American International Chemical Inc, AT Planejamento E Desenvolvimento De Negocios Ltd, Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd, among others. Approximately 45% of the company's revenue comes from its top 10 customers.

In FY23, the company generated 20% of its revenues domestically and 80% from exports. Asia and Europe contributed the most to the company's revenue, followed by Latin America and North America.

The company operates a backwards-integrated production facility located in Lote, Parshuram in Maharashtra. It spans 23,806 square meters and is divided into four blocks based on therapy. The facility includes a reactor with a capacity of 547 KL. It has approvals from various regulatory bodies including USFDA, EDQM and EUGMP. The company has also received marketing auithorisations from AIFA in Italy, TGA in Australia, BfArM in Germany, KFDA in Korea, PMDA in Japan, SFDA in China and COFEPRIS in Mexico.

The facility features designated sections for warehouse, production, finished products and dedicated blocks for different therapeutic segments. As part of the company's capacity expansion plan, the facility is projected to reach approximately 1000+ KL by 2024. The facility in Lote also houses a DSIR-approved R&D facility. The company has plans to expand its product segments within its portfolio and is in the process of establishing two new R&D centres.

In FY23, Supriya Lifescience Limited expanded its manufacturing capabilities by incorporating four new laboratories into its existing facility at Lote. Construction is also underway for a manufacturing facility with a capacity of 330 KL. It is anticipated to become operational by February 2024.

By the end of FY23, the company had submitted 15 active Drug Master Files (DMFs) to the USFDA. It also submitted nine active Certificates of Suitability (CEPs) to the European Directorate for the Quality of Medicines and Healthcare for its API products.

Financial Highlights

The company’s revenue from operations in FY23 stood at ₹460.9 crore, down 13.2% compared to ₹530 crore in FY22. The net profit dropped to ₹89.8 crore in FY23 compared to ₹151.8 crore in FY22. In FY23, the company’s earnings before interest, tax, depreciation and amortization (EBITDA) decreased to ₹129 crore compared to ₹214 crore in FY22. The company's earnings per share (EPS) stood at ₹11.16 in FY23 compared to ₹18.86 in FY22.

Supriya Lifescience Key indicators

arrow

52 week high

₹424.00

52 week low

₹233.30

P/E ratio

25.95

P/B ratio

3.76

ROE

13.66%

ROCE

18.72%

Dividend yield

0.21%

Debt/Equity ratio

0.02

EPS

11.16

Learn more

Investment checklist: (5/6)

arrow
check status

Equity returns

check status

Dividend returns

check status

Safety factor

check status

Growth factor

check status

Debt vs Equity

check status

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst ratings:

Buy

arrow

Buy

100%

Hold

0%

Sell

0%

This analysis is based on the reviews of 2 experts in the last 7 days

Fundamentals

Financial ratios

arrow
  • Profitability

  • Operational

  • Valuation

Operating profit margin

26.8%

Net profit margin

17.4%

ROE

13.66%

ROA

11.56%

ROCE

18.72%

Learn more

Supriya Lifescience Shareholder returns

arrow

1 day

+1.00%

1 week

+8.20%

1 month

+2.26%

3 months

+23.97%

1 year

+56.70%

3 years

-1.75%

5 years

-1.75%

Supriya Lifescience Share Price history

arrow
DayOpenCloseDay’s change
Thu, Jun 13 2024
₹382.15
₹384.00
+1.00%
Wed, Jun 12 2024
₹378.30
₹380.20
+1.41%
Tue, Jun 11 2024
₹367.95
₹374.90
+2.15%
Mon, Jun 10 2024
₹361.70
₹367.00
+1.62%
Fri, Jun 7 2024
₹356.00
₹361.15
+1.76%
Thu, Jun 6 2024
₹355.00
₹354.90
+2.07%
Wed, Jun 5 2024
₹339.00
₹347.70
+3.21%
Tue, Jun 4 2024
₹364.90
₹336.90
-6.22%

Shareholding info

arrow

Promoters (68.3%)

Mutual Funds (0.05%)

Retail and other (21.04%)

Foreign institutions-FII (5.37%)

Other domestic institutions (5.24%)

Promoters

Learn more

Events

Corporate actions

arrow
  • Dividend • ₹0.6/share

    Ex date 15 Sep 2023

    expand tab
  • Dividend • ₹0.6/share

    Ex date 01 Sep 2022

    expand tab

Learn more

Frequently asked questions